Aethlon Medical, Inc. provided an update on December 20, 2024, regarding the potential utility of its Hemopurifier device in treating H5N1 avian influenza, commonly known as Bird Flu. This update follows recent inquiries and reports of H5N1 isolation in dairy cows and human cases.
Preclinical in vitro studies conducted by Battelle labs demonstrated that a miniature version of the Aethlon Hemopurifier removed 99% of the H5N1 virus following six hours of treatment. The device is designed to remove enveloped viruses and extracellular vesicles from the bloodstream by binding to mannose on their surface.
The Hemopurifier holds a 'breakthrough device' designation with the FDA for life-threatening viruses for which no effective treatment exists. Aethlon Medical stated it will monitor the situation and interact with health authorities if cases increase and current treatments prove ineffective.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.